{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:10:08Z","timestamp":1747203008224,"version":"3.40.5"},"reference-count":120,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,25]]},"DOI":"10.20945\/2359-3997000000335","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T18:33:15Z","timestamp":1615314795000},"source":"Crossref","is-referenced-by-count":6,"title":["Management of hypopituitarism: a perspective from the Brazilian Society of Endocrinology and Metabolism"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-8548","authenticated-orcid":false,"given":"Heraldo Mendes","family":"Garmes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-7941","authenticated-orcid":false,"given":"C\u00e9sar Luiz","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-3386","authenticated-orcid":false,"given":"Paulo Augusto Carvalho","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-9552","authenticated-orcid":false,"given":"Manoel Ricardo Alves","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2405-0013","authenticated-orcid":false,"given":"Silvia Regina Correa da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4804-1525","authenticated-orcid":false,"suffix":"Filho","given":"Julio Zaki","family":"Abucham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-4476","authenticated-orcid":false,"given":"Nina Rosa de Castro","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4815-6963","authenticated-orcid":false,"given":"Lucio","family":"Vilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3824-0750","authenticated-orcid":false,"given":"Luiz Henrique Corr\u00eaa","family":"Portari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"M\u00f4nica Roberto","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-3192","authenticated-orcid":false,"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3363-3803","authenticated-orcid":false,"given":"Luciana Ansaneli","family":"Naves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-5776","authenticated-orcid":false,"given":"Mauro Ant\u00f4nio","family":"Czepielewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1789-0068","authenticated-orcid":false,"given":"Tobias Skrebsky de","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-1301","authenticated-orcid":false,"given":"Felipe Henning Gaia","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-6756","authenticated-orcid":false,"given":"Andrea","family":"Glezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-5201","authenticated-orcid":false,"given":"Marcello Delano","family":"Bronstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"9571","key":"key20210309133310_B1","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(07)60673-4","article-title":"Hypopituitarism","volume":"369","author":"Schneider","year":"2007","unstructured":"1. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla G-K, Ghigo E. Hypopituitarism. Lancet. 2007;369(9571):1461-70.","journal-title":"Lancet"},{"issue":"6","key":"key20210309133310_B2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1365-2265.2001.01406.x","article-title":"Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain","author":"Regal","year":"2001","unstructured":"2. Regal M, P\u00e1ramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf). 2001(6):735-40.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"key20210309133310_B3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.1.02191","article-title":"Incidence of GH deficiency \u2013 a nationwide study","volume":"155","author":"Stochholm","year":"2006","unstructured":"3. Stochholm K, Gravholt CH, Laursen T, J\u00f8rgensen JO, Laurberg P, Andersen M, et al. Incidence of GH deficiency \u2013 a nationwide study. Eur J Endocrinol. 2006;155(1):61-71.","journal-title":"Eur J Endocrinol"},{"issue":"8710","key":"key20210309133310_B4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0140-6736(90)91812-O","article-title":"Premature mortality due to cardiovascular disease in hypopituitarism","volume":"336","author":"Ros\u00e9n","year":"1990","unstructured":"4. Ros\u00e9n T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336(8710):285-8.","journal-title":"Lancet"},{"issue":"1","key":"key20210309133310_B5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12020-016-1159-3","article-title":"Mortality in adults with hypopituitarism: a systematic review and meta-analysis","volume":"56","author":"Jasim","year":"2017","unstructured":"5. Jasim S, Alahdab F, Ahmed AT, Tamhane S, Prokop LJ, Nippoldt TB, et al. Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine. 2017;56(1):33-42.","journal-title":"Endocrine"},{"key":"key20210309133310_B6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/jc.2014-3787","article-title":"Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies","volume":"100","author":"Pappachan","year":"2015","unstructured":"6. Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN. Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab. 2015;100:1405-11.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20210309133310_B7","first-page":"78","article-title":"Advancements in the gold standard: Measuring steroid sex hormones by mass spectrometry","volume":"269","author":"Conklin","year":"2020","unstructured":"7. Conklin SE, Knezevic CE. Advancements in the gold standard: Measuring steroid sex hormones by mass spectrometry. Clin Biochem. 2020;269:78-84.","journal-title":"Clin Biochem"},{"key":"key20210309133310_B8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3389\/fendo.2019.00534","article-title":"Insulin Sensitivity Is Not Decreased in Adult Patients With Hypopituitarism Without Growth Hormone Replacement","volume":"10","author":"Castillo","year":"2019","unstructured":"8. Castillo AR, de Souza AL, Alegre SM, Atala YB, Zantut-Wittmann DE, Garmes HM. Insulin Sensitivity Is Not Decreased in Adult Patients With Hypopituitarism Without Growth Hormone Replacement. Front Endocrinol (Lausanne). 2019;10:534.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"key20210309133310_B9","doi-asserted-by":"crossref","first-page":"e1847","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial","volume":"105","author":"S\u00e4vendahl","year":"2020","unstructured":"9. S\u00e4vendahl L, Battelino T, Brod M, H\u00f8jby Rasmussen M, Horikawa R, Juul RV, et al. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial. J Clin Endocrinol Metab. 2020;105(4):e1847-61.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20210309133310_B10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/cen.13554","article-title":"Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis","volume":"88","author":"Guarnotta","year":"2018","unstructured":"10. Guarnotta V, Ciresi A, Pillitteri G, Giordano C. Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin Endocrinol (Oxf). 2018;88(5):665-72.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"key20210309133310_B11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/a-0822-3637","article-title":"Congenital Hypopituitarism: Various Genes, Various Phenotypes","volume":"51","author":"Xatzipsalti","year":"2019","unstructured":"11. Xatzipsalti M, Voutetakis A, Stamoyannou L, Chrousos GP, Kanaka-Gantenbein C. Congenital Hypopituitarism: Various Genes, Various Phenotypes. Horm Metab Res. 2019;51(2):81-90.","journal-title":"Horm Metab Res"},{"issue":"4","key":"key20210309133310_B12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11102-020-01048-w","article-title":"Metabolic syndrome and its components in adult hypopituitary patients","volume":"23","author":"Abe","year":"2020","unstructured":"12. Abe SY, Dos Santos KS, Barbosa BFB, Biondo CMP, Takito D, Hayashi SK, et al. Metabolic syndrome and its components in adult hypopituitary patients. Pituitary. 2020;23(4):409-16.","journal-title":"Pituitary"},{"key":"key20210309133310_B13","doi-asserted-by":"crossref","first-page":"16092","DOI":"10.1038\/nrdp.2016.92","article-title":"Sheehan syndrome","volume":"2","author":"Karaca","year":"2016","unstructured":"13. Karaca Z, Laway BA, Dokmetas HS, Atmaca H, Kelestimur F. Sheehan syndrome. Nat Rev Dis Primers. 2016;2:16092.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"key20210309133310_B14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.298.12.1429","article-title":"Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review","volume":"298","author":"Schneider","year":"2007","unstructured":"14. Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA. 2007;298(12):1429-38.","journal-title":"JAMA"},{"issue":"6","key":"key20210309133310_B15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.6061\/clinics\/2013(06)04","article-title":"Pituitary deficiency after aneurysmal subarachnoid hemorrhage","volume":"68","author":"Pereira","year":"2013","unstructured":"15. Pereira JL, Albuquerque LA, Dellaretti M, Carvalho GT, Vieira G Jr, Brochado VM, et al. Pituitary deficiency after aneurysmal subarachnoid hemorrhage. Clinics (Sao Paulo). 2013;68(6):745-9.","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"key20210309133310_B16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1227\/NEU.0000000000001157","article-title":"Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis","volume":"79","author":"Can","year":"2016","unstructured":"16. Can A, Gross BA, Smith TR, Dammers R, Dirven CM, Woodmansee WW, et al. Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis. Neurosurgery. 2016;79(2):253-64.","journal-title":"Neurosurgery"},{"issue":"2","key":"key20210309133310_B17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/17446651.2020.1733411","article-title":"Long-term neuroendocrine consequences of traumatic brain injury and strategies for management","volume":"15","author":"Hacioglu","year":"2020","unstructured":"17. Hacioglu A, Kelestimur F, Tanriverdi F. Long-term neuroendocrine consequences of traumatic brain injury and strategies for management. Expert Rev Endocrinol Metab. 2020;15(2):123-39.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1","key":"key20210309133310_B18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrendo.2017.103","article-title":"Chronic endocrine consequences of traumatic brain injury \u2013 what is the evidence?","volume":"14","author":"Klose","year":"2018","unstructured":"18. Klose M, Feldt-Rasmussen U. Chronic endocrine consequences of traumatic brain injury \u2013 what is the evidence? Nat Rev Endocrinol. 2018;14(1):57-62.","journal-title":"Nat Rev Endocrinol"},{"key":"key20210309133310_B19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fendo.2018.00029","article-title":"Luteinizing Hormone and Testosterone Levels during Acute Phase of Severe Traumatic Brain Injury: Prognostic Implications for Adult Male Patients","volume":"9","author":"Hohl","year":"2018","unstructured":"19. Hohl A, Zanela FA, Ghisi G, Ronsoni MF, Diaz AP, Schwarzbold ML, et al. Luteinizing Hormone and Testosterone Levels during Acute Phase of Severe Traumatic Brain Injury: Prognostic Implications for Adult Male Patients. Front Endocrinol (Lausanne). 2018;9:29.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"key20210309133310_B20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11102-019-00937-z","article-title":"Pituitary dysfunction due to sports-related traumatic brain injury","volume":"22","author":"Hacioglu","year":"2019","unstructured":"20. Hacioglu A, Kelestimur F, Tanriverdi F. Pituitary dysfunction due to sports-related traumatic brain injury. Pituitary. 2019;22(3):322-31.","journal-title":"Pituitary"},{"issue":"1","key":"key20210309133310_B21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000480086","article-title":"New Molecular, Biological, and Immunological Agents Inducing Hypophysitis","volume":"106","author":"Angelousi","year":"2018","unstructured":"21. Angelousi A, Chatzellis E, Kaltsas G. New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. Neuroendocrinology. 2018;106(1):89-100.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"key20210309133310_B22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40842-016-0034-8","article-title":"Hypophysitis: Evaluation and Management","volume":"2","author":"Faje","year":"2016","unstructured":"22. Faje A. Hypophysitis: Evaluation and Management. Clin diabetes Endocrinol. 2016;2(1):15.","journal-title":"Clin diabetes Endocrinol"},{"issue":"3","key":"key20210309133310_B23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","unstructured":"23. Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf). 2016;85(3):331-9.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"key20210309133310_B24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","unstructured":"24. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195-207.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"key20210309133310_B25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens","volume":"4","author":"Barroso-Sousa","year":"2018","unstructured":"25. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. JAMA Oncol. 2018;4(2):173.","journal-title":"JAMA Oncol"},{"issue":"10","key":"key20210309133310_B26","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors","volume":"2","author":"Friedman","year":"2016","unstructured":"26. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors. JAMA Oncol. 2016;2(10):1346.","journal-title":"JAMA Oncol"},{"issue":"2","key":"key20210309133310_B27","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1530\/EJE-19-0154","article-title":"Diagnosis of endocrine disease: Drug-induced endocrinopathies and diabetes: a combo-endocrinology overview","volume":"181","author":"Diamanti-Kandarakis","year":"2019","unstructured":"27. Diamanti-Kandarakis E, Duntas L, Kanakis GA, Kandaraki E, Karavitaki N, Kassi E, et al. Diagnosis of endocrine disease: Drug-induced endocrinopathies and diabetes: a combo-endocrinology overview. Eur J Endocrinol. 2019;181(2):R73-105.","journal-title":"Eur J Endocrinol"},{"key":"key20210309133310_B28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.33029\/9704-4951-6-PEND-1-848","volume-title":"Williams Textbook of Endocrinology","author":"Melmed","year":"2020","unstructured":"28. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ. Williams Textbook of Endocrinology 14th edition, 2020:184-235.","edition":"14th edition"},{"issue":"10058","key":"key20210309133310_B29","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/S0140-6736(16)30053-8","article-title":"Hypopituitarism","volume":"388","author":"Higham","year":"2016","unstructured":"29. Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet. 2016;388(10058):2403-15.","journal-title":"Lancet"},{"issue":"11","key":"key20210309133310_B30","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Fleseriu","year":"2016","unstructured":"30. Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(11):3888-921.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20210309133310_B31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.20945\/2359-3997000000188","article-title":"Insulin signaling in the whole spectrum of GH deficiency","volume":"63","author":"Garmes","year":"2019","unstructured":"31. Garmes HM, Castillo AR. Insulin signaling in the whole spectrum of GH deficiency. Arch Endocrinol Metab. 2019;63(6):582-91.","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"key20210309133310_B32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1530\/EJE-06-0699","article-title":"The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH","volume":"156","author":"van der Klaauw","year":"2007","unstructured":"32. van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol. 2007;156(4):455-62.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"key20210309133310_B33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/jc.2009-1326","article-title":"International Hypopituitary Control Complications Study Advisory Board. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement","volume":"95","author":"Attanasio","year":"2010","unstructured":"33. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, et al.; International Hypopituitary Control Complications Study Advisory Board. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab. 2010;95(1):74-81.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20210309133310_B34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1530\/EJE-11-0599","article-title":"Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis","volume":"165","author":"Verhelst","year":"2011","unstructured":"34. Verhelst J, Mattsson AF, Luger A, Thunander M, G\u00f3th MI, Koltowska-H\u00e4ggstr\u00f6m M, et al. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol. 2011;165(6):881-9.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"key20210309133310_B35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrendo.2017.47","article-title":"Central hypothyroidism \u2013 a neglected thyroid disorder","volume":"13","author":"Beck-Peccoz","year":"2017","unstructured":"35. Beck-Peccoz P, Rodari G, Giavoli C, Lania A. Central hypothyroidism \u2013 a neglected thyroid disorder. Nature Reviews Endocrinology. 2017;13(10):588-98.","journal-title":"Nature Reviews Endocrinology"},{"issue":"5","key":"key20210309133310_B36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000491388","article-title":"2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism","volume":"7","author":"Persani","year":"2018","unstructured":"36. Persani L, Brabant G, Dattani M, Bonomi M, Feldt-Rasmussen U, Fliers E, et al. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. Eur Thyroid J. 2018;7(5):225-37.","journal-title":"Eur Thyroid J"},{"issue":"1","key":"key20210309133310_B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/eje.0.1500001","article-title":"Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients","volume":"150","author":"Alexopoulou","year":"2004","unstructured":"37. Alexopoulou O, Beguin C, De Nayer P, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol. 2004;150(1):1-8.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"key20210309133310_B38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-11-0907","article-title":"Diagnosis of subclinical central hypothyroidism in patients with hypothalamic-pituitary disease by Doppler echocardiography","volume":"166","author":"Doin","year":"2012","unstructured":"38. Doin FC, Rosa-Borges M, Martins MRA, Mois\u00e9s VA, Abucham J. Diagnosis of subclinical central hypothyroidism in patients with hypothalamic-pituitary disease by Doppler echocardiography. Eur J Endocrinol. 2012;166(4):631-40.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"key20210309133310_B39","first-page":"924","article-title":"Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism","volume":"84","author":"Ferretti","year":"1999","unstructured":"39. Ferretti E, Persani L, Jaffrain-Rea ML, Giambona S, Tamburrano G, Beck-Peccoz P. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab. 1999;84(3):924-9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key20210309133310_B40","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1210\/jc.2007-0297","article-title":"Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine","volume":"92","author":"Slawik","year":"2007","unstructured":"40. Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab. 2007;92(11):4115-22.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key20210309133310_B41","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1210\/jc.2007-0941","article-title":"Growth hormone replacement improves thyroxine biological effects: Implications for management of central hypothyroidism","volume":"92","author":"Martins","year":"2007","unstructured":"41. Martins MRA, Doin FC, Komatsu WR, Barros-Neto TL, Moises VA, Abucham J. Growth hormone replacement improves thyroxine biological effects: Implications for management of central hypothyroidism. J Clin Endocrinol Metab. 2007;92(11):4144-53.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"key20210309133310_B42","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1210\/jc.2013-1610","article-title":"Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients","volume":"98","author":"Klose","year":"2013","unstructured":"42. Klose M, Marina D, Hartoft-Nielsen ML, Klefter O, Gavan V, Hilsted L, et al. Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. J Clin Endocrinol Metab. 2013;98(9):3802-10.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20210309133310_B43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1530\/EJE-14-0097","article-title":"Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism","volume":"170","author":"Mazziotti","year":"2014","unstructured":"43. Mazziotti G, Mormando M, Cristiano A, Bianchi A, Porcelli T, Giampietro A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol. 2014;170(6):893-9.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"key20210309133310_B44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/thy.2016.0457","article-title":"2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum","volume":"27","author":"Alexander","year":"2017","unstructured":"44. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-89.","journal-title":"Thyroid"},{"key":"key20210309133310_B45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000443915","article-title":"Secondary Adrenal Insufficiency: Where Is It Hidden and What Does It Look Like?","volume":"46","author":"Guaraldi","year":"2016","unstructured":"45. Guaraldi F, Karamouzis I, Berardelli R, D\u2019Angelo V, Rampino A, Zichi C, et al. Secondary Adrenal Insufficiency: Where Is It Hidden and What Does It Look Like? Front Horm Res. 2016;46:159-70.","journal-title":"Front Horm Res"},{"issue":"3","key":"key20210309133310_B46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","article-title":"Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","unstructured":"46. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015;3(3):216-26.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"key20210309133310_B47","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: review of the literature","volume":"38","author":"Araujo","year":"2015","unstructured":"47. Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV. Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest. 2015;38(11):1159-66.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"key20210309133310_B48","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1210\/jc.2012-4059","article-title":"Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality","volume":"98","author":"Burman","year":"2013","unstructured":"48. Burman P, Mattsson AF, Johannsson G, H\u00f6ybye C, Holmer H, Dahlqvist P, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013;98(4):1466-75.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20210309133310_B49","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1530\/EJE-14-0824","article-title":"Extensive expertise in endocrinology. Adrenal crisis","volume":"172","author":"Allolio","year":"2015","unstructured":"49. Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol. 2015;172(3):R115-24.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"key20210309133310_B50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/CCM.0000000000002840","article-title":"Corticosteroid Guideline Task Force of SCCM and ESICM. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017","volume":"46","author":"Pastores","year":"2018","unstructured":"50. Pastores SM, Annane D, Rochwerg B; Corticosteroid Guideline Task Force of SCCM and ESICM. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med. 2018;46(1):146-8.","journal-title":"Crit Care Med"},{"key":"key20210309133310_B51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12020-017-1356-8","article-title":"Glucagon stimulation test: has its time come?","volume":"57","author":"Boguszewski","year":"2017","unstructured":"51. Boguszewski CL. Glucagon stimulation test: has its time come? Endocrine. 2017;57:361-3.","journal-title":"Endocrine"},{"issue":"3","key":"key20210309133310_B52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2265.1998.00555.x","article-title":"Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders","volume":"49","author":"Clark","year":"1998","unstructured":"52. Clark PM, Neyton I, Raggatt PR, Sheppard MC, Stewart PM. Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clin Endocrinol (Oxf). 1998;49(3):287-92.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"key20210309133310_B53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1210\/jc.2015-1700","article-title":"ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis","volume":"101","author":"Ospina","year":"2016","unstructured":"53. Ospina NS, Al Nofal A, Bancos I, Javed A, Benkhadra K, Kapoor E, et al. ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2016;101(2):427-34.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20210309133310_B54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1472-6890-14-33","article-title":"Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction","volume":"14","author":"Krasowski","year":"2014","unstructured":"54. Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL, Ekins S. Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. BMC Clin Pathol. 2014;14:33.","journal-title":"BMC Clin Pathol"},{"issue":"2","key":"key20210309133310_B55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11154-013-9240-1","article-title":"The use of mass spectrometry to improve the diagnosis and the management of the HPA axis","volume":"14","author":"Monaghan","year":"2013","unstructured":"55. Monaghan PJ, Keevil BG, Trainer PJ. The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Rev Endocr Metab Disord. 2013;14(2):143-57.","journal-title":"Rev Endocr Metab Disord"},{"key":"key20210309133310_B56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/978-3-030-15950-4_39","article-title":"Trends in Analysis of Cortisol and Its Derivatives","volume":"1140","author":"Boolani","year":"2019","unstructured":"56. Boolani A, Channaveerappa D, Dupree EJ, Jayathirtha M, Aslebagh R, Grobe S, et al. Trends in Analysis of Cortisol and Its Derivatives. Adv Exp Med Biol. 2019;1140:649-64.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"key20210309133310_B57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","unstructured":"57. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-89.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20210309133310_B58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6823-12-8","article-title":"Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey","volume":"12","author":"Forss","year":"2012","unstructured":"58. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocr Disord. 2012;12:8.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"key20210309133310_B59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4158\/EP161428.OR","article-title":"Glucocorticoid Replacement Regimens in Chronic Adrenal Insufficiency: A Systematic Review and Meta-Analysis","volume":"23","author":"Al Nofal","year":"2017","unstructured":"59. Al Nofal A, Bancos I, Benkhadra K, Ospina NM, Javed A, Kapoor E, et al. Glucocorticoid Replacement Regimens in Chronic Adrenal Insufficiency: A Systematic Review and Meta-Analysis. Endocr Pract. 2017;23(1):17-31.","journal-title":"Endocr Pract"},{"issue":"6","key":"key20210309133310_B60","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1210\/js.2019-00046","article-title":"Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice?","volume":"3","author":"Stewart","year":"2019","unstructured":"60. Stewart PM. Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice? J Endocr Soc. 2019;3(6):1150-3.","journal-title":"J Endocr Soc"},{"issue":"3","key":"key20210309133310_B61","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/cen.13267","article-title":"the EU-AIR Investigators. Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity \u2013 data from the EU-AIR","volume":"86","author":"Murray","year":"2017","unstructured":"61. Murray RD, Ekman B, Uddin S, Marelli C, Quinkler M, Zelissen PM, the EU-AIR Investigators. Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity \u2013 data from the EU-AIR. Clin Endocrinol (Oxf). 2017;86(3):340-6.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"key20210309133310_B62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/cen.12603","article-title":"Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy","volume":"82","author":"Johannsson","year":"2015","unstructured":"62. Johannsson G, Falorni A, Skrtic S, Lennern\u00e4s H, Quinkler M, Monson JP, et al. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf). 2015;82(1):2-11.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"key20210309133310_B63","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1210\/er.2018-00116","article-title":"Clinical Management of Congenital Hypogonadotropic Hypogonadism","volume":"40","author":"Young","year":"2019","unstructured":"63. Young J, Xu C, Papadakis GE, Acierno JS, Maione L, Hietam\u00e4ki J, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocr Rev. 2019;40(2):669-710.","journal-title":"Endocr Rev"},{"key":"key20210309133310_B64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fendo.2019.00345","article-title":"Metabolic disorders and male hypogonadotropic hypogonadism","volume":"10","author":"Pivonello","year":"2019","unstructured":"64. Pivonello R, Menafra D, Riccio E, Garifalos F, Mazzella M, de Angelis C, et al. Metabolic disorders and male hypogonadotropic hypogonadism. Front Endocrinol (Lausanne). 2019;10:345.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"key20210309133310_B65","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41569-019-0211-4","article-title":"Testosterone replacement therapy and cardiovascular risk","volume":"16","author":"Gagliano-Juc\u00e1","year":"2019","unstructured":"65. Gagliano-Juc\u00e1 T, Basaria S. Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. 2019;16(9):555-74.","journal-title":"Nat Rev Cardiol"},{"issue":"9254","key":"key20210309133310_B66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group","volume":"357","author":"Tomlinson","year":"2001","unstructured":"66. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357(9254):425-31.","journal-title":"Lancet"},{"issue":"5","key":"key20210309133310_B67","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline","volume":"103","author":"Bhasin","year":"2018","unstructured":"67. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-44.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"key20210309133310_B68","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122153","article-title":"Management of hypopituitarism","volume":"8","author":"Alexandraki","year":"2019","unstructured":"68. Alexandraki KI, Grossman A. Management of hypopituitarism. J Clin Med. 2019;8(12). pii: E2153.","journal-title":"J Clin Med"},{"key":"key20210309133310_B69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.12688\/f1000research.10102.1","article-title":"Treatment of hypogonadism: current and future therapies","volume":"6","author":"Thirumalai","year":"2017","unstructured":"69. Thirumalai A, Berkseth KE, Amory JK. Treatment of hypogonadism: current and future therapies. F1000Res. 2017;6:68.","journal-title":"F1000Res"},{"key":"key20210309133310_B70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.metabol.2018.03.007","article-title":"Testosterone replacement therapy: For whom, when and how?","volume":"86","author":"Tsametis","year":"2018","unstructured":"70. Tsametis CP, Isidori AM. Testosterone replacement therapy: For whom, when and how? Metabolism. 2018;86:69-78.","journal-title":"Metabolism"},{"issue":"4","key":"key20210309133310_B71","first-page":"577","article-title":"Testosterone depot injection in male hypogonadism: a critical appraisal","volume":"2","author":"Yassin","year":"2007","unstructured":"71. Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin Interv Aging. 2007;2(4):577-90.","journal-title":"Clin Interv Aging"},{"issue":"8","key":"key20210309133310_B72","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1210\/clinem\/dgaa238","article-title":"A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men","volume":"105","author":"Swerdloff","year":"2020","unstructured":"72. Ronald S Swerdloff, Christina Wang, William B White, Jed Kaminetsky, Marc C Gittelman, James A Longstreth, Robert E Dudley, Theodore M Danoff. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. J Clin Endocrinol Metab. 2020;105(8):2515-31.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"key20210309133310_B73","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1210\/js.2019-00183","article-title":"Efficacy of nasal testosterone gel (Natesto\u00ae) stratified by baseline endogenous testosterone levels","volume":"3","author":"Gronski","year":"2019","unstructured":"73. Gronski MA, Grober ED, Gottesman IS, Ormsby RW, Bryson N. Efficacy of nasal testosterone gel (Natesto\u00ae) stratified by baseline endogenous testosterone levels. J Endocr Soc. 2019;3(9):1652-62.","journal-title":"J Endocr Soc"},{"issue":"3","key":"key20210309133310_B74","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.juro.2018.09.057","article-title":"A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector","volume":"201","author":"Kaminetsky","year":"2019","unstructured":"74. Kaminetsky JC, McCullough A, Hwang K, Jaffe JS, Wang C, Swerdloff RS. A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. J Urol. 2019;201(3):587-94.","journal-title":"J Urol"},{"key":"key20210309133310_B75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000485997","article-title":"Metabolic Syndrome in Hypopituitarism","volume":"49","author":"Milji\u0107","year":"2018","unstructured":"75. Milji\u0107 D, Popovic V. Metabolic Syndrome in Hypopituitarism. Front Horm Res. 2018;49:1-19.","journal-title":"Front Horm Res"},{"issue":"8","key":"key20210309133310_B76","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/humrep\/deaa124","article-title":"Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies","volume":"35","author":"Zhu","year":"2020","unstructured":"76. Zhu D, Chung HF, Dobson AJ, Pandeya N, Brunner EJ, Kuh D, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod. 2020 Aug 1;35(8):1933-43.","journal-title":"Hum Reprod"},{"issue":"1","key":"key20210309133310_B77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2265.2006.02545.x","article-title":"Hypopituitarism and mortality in pituitary adenoma","volume":"65","author":"Lindholm","year":"2006","unstructured":"77. Lindholm J, Nielsen EH, Bjerre P, Christiansen JS, Hagen C, Juul S, et al. Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol (Oxf). 2006;65(1):51-8.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"key20210309133310_B78","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11102-018-0895-1","article-title":"Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism","volume":"21","author":"Olivius","year":"2018","unstructured":"78. Olivius C, Landin-Wilhelmsen K, Olsson DS, Johannsson G, Tivesten \u00c5. Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism. Pituitary. 2018;21(5):445-53.","journal-title":"Pituitary"},{"issue":"1","key":"key20210309133310_B79","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.beem.2017.03.003","article-title":"Sex steroids and the GH axis: Implications for the management of hypopituitarism","volume":"31","author":"Birzniece","year":"2017","unstructured":"79. Birzniece V, Ho KKY. Sex steroids and the GH axis: Implications for the management of hypopituitarism. Best Pract Res Clin Endocrinol Metab. 2017;31(1):59-69.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"key20210309133310_B80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/0004-2730000003044","article-title":"Hormone replacement therapy in menopause","volume":"58","author":"Pardini","year":"2014","unstructured":"80. Pardini D. Hormone replacement therapy in menopause. Arq Bras Endocrinol Metabol. 2014;58(2):172-81.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"4","key":"key20210309133310_B81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/09513590.2016.1257602","article-title":"Standard hormone therapy is inadequate for bone density in premature ovarian insufficiency","volume":"33","author":"Giraldo","year":"2017","unstructured":"81. Giraldo H, Benetti-Pinto C, Ferreira V, Garmes H, Yela D, Giraldo P. Standard hormone therapy is inadequate for bone density in premature ovarian insufficiency. Gynecol Endocrinol. 2017;33(4):283-86.","journal-title":"Gynecol Endocrinol"},{"issue":"10","key":"key20210309133310_B82","first-page":"755","article-title":"Use of ultrasonographic cut point for diagnosing endometrial pathology in postmenopausal women with multiple risk factors for endometrial cancer","volume":"53","author":"Nutis","year":"2008","unstructured":"82. Nutis M, Garc\u00eda KM, Nuwayhid B, Mulla Z, ElMasri W. Use of ultrasonographic cut point for diagnosing endometrial pathology in postmenopausal women with multiple risk factors for endometrial cancer. J Reprod Med. 2008;53(10):755-9.","journal-title":"J Reprod Med"},{"issue":"2","key":"key20210309133310_B83","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/humupd\/dmy039","article-title":"The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review","volume":"25","author":"Oliver-Williams","year":"2019","unstructured":"83. Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update. 2019;25(2):257-71.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"key20210309133310_B84","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1210\/jcem.87.5.8494","article-title":"Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial","volume":"87","author":"Johannsson","year":"2002","unstructured":"84. Johannsson G, Burman P, Wir\u00e9n L, Engstr\u00f6m BE, Nilsson AG, Ottosson M, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab. 2002;87(5):2046-52.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20210309133310_B85","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1210\/jc.2014-2260","article-title":"Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline","volume":"99","author":"Wierman","year":"2014","unstructured":"85. Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20210309133310_B86","doi-asserted-by":"crossref","first-page":"190","DOI":"10.20945\/2359-3997000000152","article-title":"Testosterone therapy for women with low sexual desire: a position statement from the Brazilian Society of Endocrinology and Metabolism","volume":"63","author":"Weiss","year":"2019","unstructured":"86. Weiss RV, Hohl A, Athayde A, Pardini D, Gomes L, Oliveira M, et al. Testosterone therapy for women with low sexual desire: a position statement from the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2019;63(3):190-8.","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"key20210309133310_B87","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/jwh.2018.7494","article-title":"Androgen Therapy in Women","volume":"29","author":"Vegunta","year":"2020","unstructured":"87. Vegunta S, Kling JM, Kapoor E. Androgen Therapy in Women. J Womens Health (Larchmt). 2020;29(1):57-64.","journal-title":"J Womens Health (Larchmt)"},{"issue":"2","key":"key20210309133310_B88","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11154-019-09530-y","article-title":"Fertility issues in aggressive pituitary tumors","volume":"21","author":"Marques","year":"2020","unstructured":"88. Marques JVO, Boguszewski CL. Fertility issues in aggressive pituitary tumors. Rev Endocr Metab Disord. 2020;21(2):225-33.","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"key20210309133310_B89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-0794-7587","article-title":"Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?","volume":"79","author":"Petersenn","year":"2019","unstructured":"89. Petersenn S, Christ-Crain M, Droste M, Finke R, Flitsch J, Kreitschmann-Andermahr I, et al. Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment? Geburtshilfe Frauenheilkd. 2019;79(4):365-74.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"key20210309133310_B90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-09-0084","article-title":"Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment","volume":"161","author":"Ribeiro","year":"2009","unstructured":"90. Ribeiro RS, Abucham J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol. 2009;161(1):163-9.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"key20210309133310_B91","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1590\/S0004-27302011000400005","article-title":"Clomiphene fails to revert hypogonadism in most male patients with conventionally treated nonfunctioning pituitary adenomas","volume":"55","author":"Ribeiro","year":"2011","unstructured":"91. Ribeiro RS, Abucham J. Clomiphene fails to revert hypogonadism in most male patients with conventionally treated nonfunctioning pituitary adenomas. Arq Bras Endocrinol Metabol. 2011;55(4):266-71.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"5","key":"key20210309133310_B92","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1210\/jc.2014-3913","article-title":"Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies","volume":"100","author":"Duarte","year":"2015","unstructured":"92. Duarte FH, Jallad RS, Bronstein MD. Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. J Clin Endocrinol Metab. 2015;100(5):1863-9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20210309133310_B93","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/jcem-66-4-862","article-title":"Failure of gonadotropin therapy secondary to chorionic gonadotropin-induced antibodies","volume":"66","author":"Thau","year":"1988","unstructured":"93. Thau RB, Goldstein M, Yamamoto Y, Burrow GN, Phillips D, Bardin CW. Failure of gonadotropin therapy secondary to chorionic gonadotropin-induced antibodies. J Clin Endocrinol Metab. 1988;66(4):862-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20210309133310_B94","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1210\/clinem\/dgz112","article-title":"Fertility and Pregnancy in Women With Hypopituitarism: A Systematic Literature Review","volume":"105","author":"Vila","year":"2020","unstructured":"94. Vila G, Fleseriu M. Fertility and Pregnancy in Women With Hypopituitarism: A Systematic Literature Review. J Clin Endocrinol Metab. 2020;105(3):e53-e65.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20210309133310_B95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.1.02191","article-title":"Incidence of GH deficiency - a nationwide study","volume":"155","author":"Stochholm","year":"2006","unstructured":"95. Stochholm K, Gravholt CH, Laursen T, J\u00f8rgensen JO, Laurberg P, Andersen M, et al. Incidence of GH deficiency - a nationwide study. Eur J Endocrinol. 2006;155(1):61-71.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"key20210309133310_B96","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-07-0631","article-title":"2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia","volume":"157","author":"Ho","year":"2007","unstructured":"96. Ho KK, 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157(6):695-700.","journal-title":"Eur J Endocrinol"},{"key":"key20210309133310_B97","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","unstructured":"97. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587-609.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20210309133310_B98","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.12688\/f1000research.12057.1","article-title":"Update on GH therapy in adults","volume":"6","author":"Boguszewski","year":"2017","unstructured":"98. Boguszewski CL. Update on GH therapy in adults. F1000Research 2017;6:2017.","journal-title":"F1000Research"},{"key":"key20210309133310_B99","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1590\/S0004-27302013000900006","article-title":"Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period","volume":"57","author":"Boguszewski","year":"2013","unstructured":"99. Boguszewski CL, Lacerda CS, Lacerda Filho L, Carvalho JA, Boguszewski MCS. Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period. Arq Bras Endocrinol Metabol. 2013;57:709-16.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"2","key":"key20210309133310_B100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1210\/jc.2013-4187","article-title":"Growth hormone should be used only for approved indications","volume":"99","author":"Clemmons","year":"2014","unstructured":"100. Clemmons DR, Molitch M, Hoffman AR, Klibanski A, Strasburger CJ, Kleinberg DL, et al. Growth hormone should be used only for approved indications. J Clin Endocrinol Metab. 2014;99(2):409-11.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20210309133310_B101","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1056\/NEJMra1817346","article-title":"Pathogenesis and diagnosis of growth hormone deficiency in adults","volume":"380","author":"Melmed","year":"2019","unstructured":"101. Melmed S. Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med. 2019;380:2551-62.","journal-title":"N Engl J Med"},{"key":"key20210309133310_B102","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ghir.2007.04.010","article-title":"Growth hormone replacement throughout life: insights into age-related responses to treatment","volume":"17","author":"Clayton","year":"2007","unstructured":"102. Clayton P, Gleeson H, Monson J, Popovic V, Shalet SM, Christiansen JS. Growth hormone replacement throughout life: insights into age-related responses to treatment. Growth Horm IGF Res. 2007;17:369-82.","journal-title":"Growth Horm IGF Res"},{"key":"key20210309133310_B103","volume-title":"Human growth hormone (somatropin) in adults with growth hormone deficiency","author":"National Institute for Health and Clinical Excellence","year":"2003","unstructured":"103. National Institute for Health and Clinical Excellence. Human growth hormone (somatropin) in adults with growth hormone deficiency. London: National Institute for Health and Clinical Excellence; 2003."},{"issue":"9","key":"key20210309133310_B104","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1590\/S0004-27302010000900010","article-title":"The Brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation","volume":"54","author":"Ribeiro-Oliveira","year":"2010","unstructured":"104. Ribeiro-Oliveira A, Mol SS, Twiss J, Alencar GA, Miranda PAC, Naves LA, et al. The Brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation. Arq Bras Endocrinol Metabol. 2010;54(9):833-41.","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"key20210309133310_B105","author":"Di\u00e1rio Oficial da Uni\u00e3o","year":"2018","unstructured":"105. Di\u00e1rio Oficial da Uni\u00e3o. Portaria Conjunta N\u00ba 28, de 30 de Novembro de 2018. Available from: http:\/\/www.in.gov.br\/materia\/-\/asset_publisher\/Kujrw0TZC2Mb\/content\/id\/55216762\/do1-2018-12-14-portaria-conjunta-n-28-de-30-de-novembro-de-2018-55216742. Accessed in: July 31, 2020.","journal-title":"Portaria Conjunta N\u00ba 28"},{"key":"key20210309133310_B106","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/cen.13147","article-title":"Growth hormone (GH) enhances anaerobic capacity: impact on physical function and quality of life in adults with GH deficiency","volume":"85","author":"Chikani","year":"2016","unstructured":"106. Chikani V, Cuneo RC, Hickman I, Ho KK. Growth hormone (GH) enhances anaerobic capacity: impact on physical function and quality of life in adults with GH deficiency. Clin Endocrinol (Oxf). 2016;85:660-8.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key20210309133310_B107","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EJE-18-0306","article-title":"Growth hormone replacement therapy in adults: 30 years of personal clinical experience","volume":"179","author":"J\u00f8rgensen","year":"2018","unstructured":"107. J\u00f8rgensen JOL, Juul A. Growth hormone replacement therapy in adults: 30 years of personal clinical experience. Eur J Endocrinol. 2018;179:R47-56.","journal-title":"Eur J Endocrinol"},{"key":"key20210309133310_B108","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-020-09605-1","article-title":"Individual sensitivity to growth hormone replacement in adults","author":"Boguszewski","year":"2020","unstructured":"108. Boguszewski CL. Individual sensitivity to growth hormone replacement in adults. Rev Endocr Metab Disord. 2020 Oct 7. doi: 10.1007\/s11154-020-09605-1.","journal-title":"Rev Endocr Metab Disord"},{"key":"key20210309133310_B109","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1210\/jc.2014-2892","article-title":"Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study","volume":"99","author":"Mo","year":"2014","unstructured":"109. Mo D, Blum WF, Rosilio M, Webb SM, Qi R, Strasburger CJ. Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study. J Clin Endocrinol Metab. 2014;99:4581-8.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20210309133310_B110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","unstructured":"110. Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174:1-9.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"key20210309133310_B111","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/er.2018-00166","article-title":"Growth Hormone\u2019s Links to Cancer","volume":"40","author":"Boguszewski","year":"2019","unstructured":"111. Boguszewski CL, Boguszewski MCDS. Growth Hormone\u2019s Links to Cancer. Endocr Rev. 2019;40(2):558-74.","journal-title":"Endocr Rev"},{"issue":"1","key":"key20210309133310_B112","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1210\/jc.2012-2940","article-title":"Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy","volume":"98","author":"Claessen","year":"2013","unstructured":"112. Claessen KM, Appelman-Dijkstra NM, Adoptie DM, Roelfsema F, Smit JW, Biermasz NR, et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab. 2013;98(1):352-61.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20210309133310_B113","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cen.13256","article-title":"The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet\u00ae International Outcome Study","volume":"86","author":"Weber","year":"2017","unstructured":"113. Weber MM, Biller BM, Pedersen BT, Pournara E, Christiansen JS, H\u00f6ybye C. The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet\u00ae International Outcome Study. Clin Endocrinol (Oxf). 2017;86(2):192-8.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key20210309133310_B114","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-16-1047","article-title":"The multiple facets of GHRH\/GH\/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation","volume":"177","author":"Aguiar-Oliveira","year":"2017","unstructured":"114. Aguiar-Oliveira MH, Souza AHO, Oliveira CRP, Campos VC, Oliveira-Neto LA, Salvatori R. The multiple facets of GHRH\/GH\/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation. Eur J Endocrinol. 2017;177:R85-97.","journal-title":"Eur J Endocrinol"},{"key":"key20210309133310_B115","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-020-01099-z","article-title":"Vasculometabolic effects in patients with congenital growth hormone deficiency with and without GH replacement therapy during adulthood","author":"Biscotto","year":"2020","unstructured":"115. Biscotto IP, Costa Hong VA, Batista RL, Mendonca BB, Arnhold IJP, Bortolotto LA, et al. Vasculometabolic effects in patients with congenital growth hormone deficiency with and without GH replacement therapy during adulthood. Pituitary. 2020 Oct 24. doi: 10.1007\/s11102-020-01099-z.","journal-title":"Pituitary"},{"issue":"11","key":"key20210309133310_B116","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1515\/jpem-2017-0210","article-title":"Effects of 1-year growth hormone replacement therapy on thyroid volume and function of the children and adolescents with idiopathic growth hormone deficiency","volume":"30","author":"Keskin","year":"2017","unstructured":"116. Keskin M, Bayramoglu E, Aycan Z. Effects of 1-year growth hormone replacement therapy on thyroid volume and function of the children and adolescents with idiopathic growth hormone deficiency. J Pediatr Endocrinol Metab. 2017;30(11):1187-90.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"23","key":"key20210309133310_B117","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1056\/NEJM200106073442302","article-title":"Increased need for thyroxine in women with hypothyroidism during estrogen therapy","volume":"344","author":"Arafah","year":"2001","unstructured":"117. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med. 2001;344(23):1743-9.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20210309133310_B118","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/er.2003-0035","article-title":"Estrogen regulation of growth hormone action","volume":"25","author":"Leung","year":"2004","unstructured":"118. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25(5):693-721.","journal-title":"Endocr Rev"},{"issue":"2","key":"key20210309133310_B119","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/EJE-11-0560","article-title":"Effects of oral and transdermal estrogen on IGF-1, IGFBP-3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study","volume":"166","author":"Isotton","year":"2012","unstructured":"119. Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA. Effects of oral and transdermal estrogen on IGF-1, IGFBP-3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. Eur J Endocrinol 2012;166(2):207-13.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"key20210309133310_B120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12020-016-1118-z","article-title":"Estrogens and selective estrogen receptor modulators in acromegaly","volume":"54","author":"Duarte","year":"2016","unstructured":"120. Duarte FH, Jallad RS, Bronstein MD. Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine. 2016;54(2):306-14.","journal-title":"Endocrine"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T18:34:56Z","timestamp":1615314896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972021005003207&lng=en&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":120,"alternative-id":["10.20945\/2359-3997000000335"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000335","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}